Evidence map›Paper›PMID 39934532›Full record

ArticleDiscover oncology2025

miR-124-3p inhibits CRC proliferation, migration, and invasion by targeting ITGB1.

Jing Li, Lisi Liu

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The Significance of Neuropilins in Gastrointestinal Cancers.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jing LiPediatrics Department, Northeast International Hospital, Shenyang, 110623, China. wojiushilj3278@126.com.
Lisi LiuTraditional Chinese Medicine School, Liaoning University of Traditional Chinese Medicine, Shenyang, 110847, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) was the third most common cause of mortality associated with cancer globally. miR-124-3p has been widely acknowledged for its pivotal role as a tumor suppressor in various malignancies. In this study, we aimed to investigate the specific functions and underlying mechanisms of miR-124-3p in CRC cell proliferation, migration and invasion. A comprehensive set of assays, including CCK-8, colony formation, wound healing assays, flow cytometry, RT-qPCR and Western blotting, were conducted to assess the impact of miR-124-3p expression on CRC cell growth. Our investigations into miR-124-3p and its potential target gene ITGB1 were facilitated through bioinformatics analysis and dual-luciferase reporter assays. To further solidify our findings, rescue experiments were executed to validate the role of miR-124-3p in regulating the proliferation, migration, and apoptosis of CRC cells, genes involving Wnt/β-catenin signaling pathway were also detected. Our study revealed that the overexpression of miR-124-3p significantly suppressed both the proliferation and migratory capabilities of CRC cells, while its downregulation had the opposite effect. Notably, ITGB1 was identified as a putative target gene of miR-124-3p, exhibiting an inverse correlation with the expression levels of miR-124-3p. Moreover, the overexpression of ITGB1 was able to abrogate the inhibitory effects exerted by miR-124-3p overexpression on CRC cell proliferation, migration, and Wnt1/β-catenin protein levels. Our results reveal that miR-124-3p targets ITGB1 to regulate CRC cell proliferation and migration may be associated with the Wnt/β-catenin signaling pathway. These findings provide that a miR-124-3p/ITGB1 axis may be a potential target for the treatment of CRC.

Indexed as

Colorectal cancerITGB1MigrationMiR-124-3pProliferation

Identifiers

PMID39934532
PMCPMC11813836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.